Johnson & Johnson Announces Health Canada NOC For RYBREVANT Combination - Quick Facts

(RTTNews) - Johnson & Johnson (JNJ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor Exon 20 insertion mutations. The Health Canada NOC is based on results from the Phase 3, randomized, open-label, multicenter PAPILLON study.

"The approval of RYBREVANT offers a promising and urgently needed new first-line treatment option and represents significant advancement for those battling this rare mutation," said Nina Devito, Co-chair, Exon20 group-Canada.

For More Such Health News, visit rttnews.com.